Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 2/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 4/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25786112 | 0.90 | IDO1 (0.40) | IDO1KDM4ETDP1DAOCES2 | |
| SCHEMBL624478 | 0.88 | RXRA (0.37) | IDO1KDM4ETDP1TACR1RXRA | |
| SCHEMBL24108532 | 0.86 | RXRA (0.46) | IDO1KDM4ETDP1TACR1RXRA | |
| SCHEMBL21854601 | 0.86 | NOTUM (0.37) | IDO1KDM4ETDP1TACR1TAAR1 | |
| SCHEMBL18051412 | 0.86 | IDO1 (0.36) | IDO1KDM4ETDP1DAO | |
| SCHEMBL17114987 | 0.86 | TDP1 (0.38) | IDO1KDM4ETDP1TACR1 | |
| SCHEMBL29940917 | 0.86 | TDP1 (0.38) | IDO1KDM4ETDP1TACR1 | |
| SCHEMBL585879 | 0.82 | RXRA (0.43) | IDO1KDM4ETACR1RXRARXRB | |
| SCHEMBL15614478 | 0.82 | HTR2A (0.36) | IDO1KDM4ETDP1TACR1 | |
| SCHEMBL25369830 | 0.82 | RPS6KA3 (0.36) | IDO1KDM4ETDP1RPS6KA3JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120004822-A | Flexible crystal optical waveguide material and preparation method and application thereof | 湖州师范学院 | 2025-05-16 | — | — | CN | claimed |
| CN-119775994-A | Light capturing system based on poly benzyl ether dendrimer, and preparation method and application thereof | 常州大学 | 2025-04-08 | — | — | CN | claimed |
| CN-111499573-A | Pressure-induced color-changing fluorescent molecule and preparation method thereof | 浙江工业大学 | 2020-08-07 | — | — | CN | claimed |
| CN-108912012-A | A kind of power causes ratio off-color material and preparation method thereof | 浙江工业大学 | 2018-11-30 | — | — | CN | claimed |
| CN-105601495-B | It is a kind of how the synthetic method of the smooth intermediate of appropriate pyrrole | 合肥利夫生物科技有限公司 | 2018-05-29 | — | — | CN | claimed |
| CN-105541593-B | A kind of synthetic method of pharmaceutical intermediate | 合肥利夫生物科技有限公司 | 2017-07-28 | — | — | CN | claimed |
| CN-105601495-A | Synthesis method of netupitant intermediates | HEFEI LEAF BIO-TECH CO LTD | 2016-05-25 | — | — | CN | claimed |
| CN-105541593-A | Method for synthesizing drug intermediate | HEFEI LIFU BIOTECHNOLOGY CO LTD | 2016-05-04 | — | — | CN | claimed |
| JP-2006521344-A | — | — | 2006-09-21 | — | — | JP | claimed |
| US-20060122224-A1 | Quinoline and quinoxaline compounds | BECHLE BRUCE M | 2006-06-08 | — | — | US | claimed |
| WO-2006032987-A1 | INDOLINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF ARTERIOSCLEROSIS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | claimed |
| EP-1622872-A1 | 1,2,4-SUBSTITUERTE 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY | Pfizer Products Inc. (US) | 2006-02-08 | — | — | EP | claimed |
| US-20040204450-A1 | Quinoline and quinoxaline compounds | PFIZER INC | 2004-10-14 | — | — | US | claimed |
| WO-2004085401-A1 | 1,2,4-SUBSTITUTED 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY | PFIZER PRODUCTS INC. (US) | 2004-10-07 | — | — | WO | claimed |
| WO-2025133660-A1 | NOVEL COMPOUNDS FOR HOST DIRECTED ANTIVIRAL STRATEGY | SORBONNE UNIVERSITE (FR) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025132449-A1 | NOVEL COMPOUNDS FOR HOST DIRECTED ANTIVIRAL STRATEGY | SORBONNE UNIVERSITE (FR) | 2025-06-26 | — | — | WO | disclosed |
| CN-120004822-A | Flexible crystal optical waveguide material and preparation method and application thereof | 湖州师范学院 | 2025-05-16 | — | — | CN | disclosed |
| US-5563133-A | NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0714891-A1 | Heterocyclic tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-06-05 | — | — | EP | disclosed |
| EP-0669320-A2 | Benzoylquinoiline derivatives | NIHON BAYER AGROCHEM K.K. (JP) | 1995-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122224-A1 | Quinoline and quinoxaline compounds | LDLR, APOB, PON1 | IDO1 1293/4885KDM4E 2642/4885TDP1 1246/4885 |
| US-20040204450-A1 | Quinoline and quinoxaline compounds | LDLR, APOB, PON1 | IDO1 1293/4885KDM4E 2642/4885TDP1 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.